Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28005050 | 0.81 | ALDH1A1 (0.36) | PIK3CDALDH1A1L3MBTL1KDM4EMEN1 | |
| SCHEMBL739637 | 0.81 | PIK3CD (0.53) | PIK3CDCYP1A2TDP1HRH3ALDH1A1 | |
| SCHEMBL3978576 | 0.80 | ALDH1A1 (0.61) | PIK3CDCYP1A2TDP1HRH3ALDH1A1 | |
| SCHEMBL299361 | 0.79 | PIK3CD (0.52) | PIK3CDCYP1A2TDP1HRH3ALDH1A1 | |
| SCHEMBL3230973 | 0.79 | MCL1 (0.34) | PIK3CDALDH1A1L3MBTL1KDM4EMEN1 | |
| SCHEMBL18702124 | 0.79 | KMT2A (0.39) | ALDH1A1L3MBTL1KDM4EMEN1KMT2A | |
| SCHEMBL14979200 | 0.78 | PIK3CD (0.50) | PIK3CDCYP1A2TDP1HRH3SMN1; SMN2 | |
| SCHEMBL926026 | 0.77 | TSHR (0.53) | TDP1HRH3ALDH1A1SMN1; SMN2RECQL | |
| SCHEMBL2576487 | 0.76 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7137154 | 0.76 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-20 | — | — | US | disclosed |
| WO-2017066227-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| CN-1150192-C | Piperidines as CCR5 modulators | — | 2004-05-19 | — | — | CN | disclosed |
| CN-1331691-A | Piperidines as CCR5 modulators | PFIZER LTD (US) | 2002-01-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | PIK3CD 4869/4885CYP1A2 456/4885TDP1 1662/4885 |
| US-20070265260-A1 | Quinazoline derivatives | TYK2, ROR1, JAK1 | PIK3CD 633/4885CYP1A2 2781/4885TDP1 1537/4885 |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | PIK3CD 1451/4885CYP1A2 3356/4885TDP1 2535/4885 |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | HSPBP1, HSF1, HSPH1 | PIK3CD 3696/4885CYP1A2 4023/4885TDP1 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.